



Report Status: Final BLIND, SAMPLE 30

Patient Information	Specimen Information	Client Information
BLIND, SAMPLE 30	Specimen: WC783844B Requisition: 0000030	Client #: 11118385 CA000159 JOSLIN LESSARD RSCH
DOB: 01/01/2001 AGE: 20 Gender: M Phone: NG Patient ID: 017C1	Collected: 12/02/2021 Received: 12/09/2021 / 08:43 EST Reported: 12/09/2021 / 23:04 EST	Attn: SARAH LESSARD 1 JOSLIN PL BOSTON, MA 02215-5306

Test Name	In Range	Out Of Range	Reference Range	Lab
LIPID PANEL, STANDARD				
CHOLESTEROL, TOTAL	169		<200 mg/dL	NL1
HDL CHOLESTEROL		36 L	> OR = 40 mg/dL	NL1
TRIGLYCERIDES	123		<150 mg/dL	NL1
LDL-CHOLESTEROL		110 H	mg/dL (calc)	NL1
Reference range: <100				

Reference range: <100

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068
(http://education.QuestDiagnostics.com/faq/FAQ164)
CHOL/HDLC RATIO 4.7

NON HDL CHOLESTEROL

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic

option.

GLUCOSE 83 65-99 mg/dL

Fasting reference interval

<130 mg/dL (calc)

<5.0 (calc)

< 8.0 mg/L

C-REACTIVE PROTEIN 5.9 INSULIN

42.5 H uIU/mL Reference Range < or = 19.6

Risk:

Optimal < or = 19.6 Moderate NA High >19.6

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

PERFORMING SITE:

NL1 QUEST DIAGNOSTICS LLC, 200 FOREST STREET 3RD FLOOR, SUITE B, MARLBOROUGH, MA 01752-3023 Laboratory Director: SALIM E KABAWAT, MD, CLIA: 22D0076229

LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

HDL CHOLESTEROL

LDL-CHOLESTEROL

110 H

mg/dL (calc)

NL1

SPECIMEN: WC783844B

Reference range: <100

NL1

NL1

NL1

NL1





Report Status: Final BLIND, SAMPLE 30

NL1

Patient Information	Specimen Information	Client Information	
BLIND, SAMPLE 30	Specimen: WC783844B Collected: 12/02/2021	Client #: 11118385	
DOB: 01/01/2001 AGE: 20 Gender: M Patient ID: 017C1	Received: 12/09/2021 / 08:43 EST Reported: 12/09/2021 / 23:04 EST		

LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)

NON HDL CHOLESTEROL 133 H <130 mg/dL (calc)
For patients with diabetes plus 1 major ASCVD risk

factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

INSULIN 42.5 H uIU/mL NL1

Reference Range < or = 19.6

Risk:

Optimal < or = 19.6

Moderate NA High >19.6

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

CLIENT SERVICES: 1.866.697.8378 SPECIMEN: WC783844B PAGE 2 OF 2